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In white populations living at moderate or low latitudes, 
melanoma has become one of the most common tumors in 
young adults. Epidemiologic studies show a complex associa­
tion with sun exposure. Risk is related positively to the levels 
of exposure typical of the place of residence, and also to 
personally controlled exposure, with the maximum risk 
being related to acute intermittent exposure. Risk also varies 
with pigmentation, family history of melanoma, and the 
presence of benign and of dysplastic nevi. The following 
methods of control of melanoma in such populations are 
discussed: the most effective methods depend on early diag­
nosis; primary prevention appears difficult and requires eval-
I n white populations, cutaneous melanoma is a major prob­lem and can be justifiably referred to as a modern epidemic. For example, New Zealand has a European-origin popula­tion living at 340 -470 south. Melanoma incidence is 210 new cases per million population per year (1983); it accounts 
for 7% of all invasive cancers. Incidence has risen by 7.5% per year 
between 1968 and 1977. One-third of patients are under 40 at 
diagnosis. Melanoma is thus by far the most common cancer in 
young adults (ages 20-39), accounting for 23% of all cancers [1]. 
The death rate is 50 per million per year, accounting for more deaths 
than cervical cancer or Hodgkin's disease [2]. Queensland, Austra­
lia, with most of its population at latitude 20° -2TS, probably has 
the highest rate in the world. The 1977 incidence rates, adjusted to 
the world population age standard, were 286 in males and 298 in 
females, compared to female rates of 188 in New Zealand non­
Maoris, 75 in Hawaii whites, 82 -87 in California whites, 44 -52 in 
Western Canada, and 2-5 in Japan [3]. 
This frequency of melanoma is a new phenomenon; in all popula­
tions that have adequate data, melanoma incidence rates have been 
rising for at least the last 40 years. Mortality rates have also increased 
very substantially, although usually at a lower rate [4]. Queensland 
mortality rates stabilized between 1963 - 1969 and 1977, although 
incidence rates are still rising [5]. 
Thus, in all white populations that have been adequately studied, 
melanoma is a major problem because of the moderate-to-high ab­
solute incidence rate, the increasing incidence, and the relatively 
young age distribution. The age at diagnosis has been dropping with 
the increase in incidence because of the underlying birth cohort 
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uation; identification of very high-risk subjects on the basis of 
family history and dysplastic nevi will affect only a very small 
proportion of melanomas; the use of simpler methods to 
identify high-risk subjects is explored. In Japan, melanoma is 
comparatively rare, but increasing as rapidly as elsewhere. 
The incidence rate of acral lentiginous melanoma appears 
similar to that in whites, comprising a large proportion of 
melanoma in Japan. Control programs cannot be designed 
rationally, since basic information on the occurrence, presen­
tation, and survival of melanoma in Japan is lacking. Some 
specific research questions are suggested. ] Invest Dermatol 
92:214S-221S, 1989 
effect [4]. In addition, treatment has not shown any major curative 
advantages (the progress in treatment striving to achieve similar 
survival results with less extensive surgery), and survival varies 
greatly with depth of diagnosis, showing a potential for early diag­
nosis. In the large Alabama series, the survival at 10 years varied 
from about 87% for tumors of < 0.76 mm depth to 30% for those of 
4.0 mm or more [6,7]. 
Logically, the control of melanoma depends on prevention and 
early diagnosis, both activities require community-based multidis­
ciplinary approaches rather than just the actions of individual physi­
cians. Fitzpatrick et al have called for an international cooperative 
effort of physicians to act against melanoma [8]. In regard to New 
Zealand, we are advocating a community-based (in this case, na­
tional) control program involving early diagnosis and prevention 
[9]. 
Epidemiology and Prevention The prevention of disease re­
quires knowledge of its etiology, and this has advanced rapidly since 
the publication of the first major analytical studies of melanoma in 
1984. 
The only clearly demonstrated external causal factor for mela­
noma is sun exposure. The role of sun exposure was implicated from 
consideration of the normal function of the melanocyte and from 
the descriptive epidemiology of melanoma, but those data suggest a 
relationship to intermittent rather than to continued exposure. 
Thus in white populations the incidence and mortality rates are 
higher at low latitudes, but have increased rapidly over time, and the 
increases have been greatest on "intermittently exposed" body sites 
such as the male back and female lower limbs [4]. An analysis of the 
site distribution suggested that the incidence rates per unit area of 
skin were similar on intermittently and on fully exposed sites [10]. 
In the United Kingdom, the disease shows the strongest positive 
relationship to the socioeconomic status of any cancer [11]. All these 
factors fit better to a hypothesis of intermittent intense exposure 
than to one of chronic exposure, and the major studies have tried to 
evaluate these alternatives. There is no generally used animal model 
for human melanoma on which the effects of different types ofUV 
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irradiation can be assessed, although UV radiation has been shown 
to promote chemically induced tumors and to have immunologic 
effects [12]. 
The two largest analytic studies are the Western Canadian and 
Western Australian studies, whose first reports were published in 
1984 [13-18]. A comparison of the main results has recently been 
publishe� [19]. Each study compared a total inc�dent series of pa­
tients with cutaneous melanoma to a population-based control 
group, and used home interviews and limited examinations by a 
nurse or lay interviewer. The basic questionnaires for both studies 
were designed by the present author. Despite the similarities, the 
results of the studies would be expected to be complementary rather 
than directly comparable, because the incidence rates in the two 
areas are very different and the levels of sun exposure correspond­
ingly higher in Australia. These differences may explain why the 
types of relationships with sun exposure seen in the two studies are 
different. 
The Canadian results fit the intermittent exposure hypothesis 
well. For superficial spreading melanoma (SSM) and nodular mela­
noma (NM), risks were increased with recreational and vacation 
exposure, but showed no increase with heavy occupational expo­
sure; however, an increased risk was seen with moderate amounts of 
occupational exposure, as would be expected from short-term or 
seasonal work. In this regard, Paffenberger et aI's prospective study 
showed an increase in melanoma in Harvard alumni who had 
worked outdoors before starting college [20]. 
Higher levels of sun exposure, through regular long-term occu­
pational exposure, showed no excess risk of SSM or NM; in fact, for 
men a protective effect was suggested [14]. This finding is con­
gruent with the lower melanoma rates seen in outdoor vs indoor 
workers within the same socioeconomic groups [11]. Lentigo ma­
ligna melanoma (LMM) showed a significantly different pattern of 
risk, with no excess at moderate occupational exposures; however, 
no consistent overall positive trend with occupational exposure was 
seen, as would be predicted from the clinical features of the subtype, 
but there were only 56 cases of LMM. LMM showed no evidence of 
an increasing risk with recreational or vacational exposure [19]. 
The Canadian results are based on a complex interview assessing 
personal exposure histories. While open to a large degree of random 
error, which will reduce any association seen, other data from the 
study suggest that the results are free from major bias. Several checks 
of validity were carried out in the Western Canada study. The case 
series does not differ from the noninterviewed cases in terms of the 
pathologic type, stage, or age of the subject. Women showed a 
higher response rate, but as all analyses are controlled for sex, this 
does not affect the results [21]. The control series have been com­
pared with census data on a number of variables, such as parity 
distribution in married women and occupational classification for 
men, and for both these the distributions are virtually identical 
[22,23]. There are several indications that problems of response bias 
are not severe. For example, for a large range of exposures such as 
smoking, alcohol use, many aspects of diet, and histories of past 
medical and skin conditions, the percentages of cases and controls 
giving positive replies are virtually identical [24]. 
.The Australian study used generally similar interview methods, With similar response rates. Various indicators of sun exposure were 
�sed. Considering first the direct personal estimates based on the 
lO�erviews, the study showed that factors corresponding to inter­
mittent exposure in general had positive associations, being signifi­
cant for SSM in terms of the proportion of all outdoor exposure at 
ages 10-24 which was recreational and for occasional summer 
work exposure. Heavier sun exposure assessed in the same way 
showed positive associations with LMM (called HMF, Hutchin­
s?n's melanotic freckle), but varied results for the other types. Posi­
tive associations for SSM and NM were seen with the usual exposure 
from summer work. However, negative associations were seen for 
total hours of outdoor exposure, particularly at ages 10-24, where 
the odds ratios were 0.5 for SSM, 0.1 for NM, and, in contrast, 2.7 
for �MM. Thus, the assessments of personal exposure in the two 
studies give similar results. The inconsistencies lie in the indirect 
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assessments of sun exposure in the Australian study. The individ­
ual's migration history was used to calculate years of residence in 
Australia, and their residence history was used to calculate the an­
nual hours of sunshine at that place. The former showed strong 
positive associations with each type of melanoma, the latter indi­
cated positive associations with SSM and LMM. Actinic damage and 
a history of skin cancer showed positive associations with all three 
subtypes. These are probably indicators of chronic exposure, but 
may also be indicators of pigmentation and host reaction to sun. The 
suggestion emerges that a subject'S melanoma risk increases with 
the amount of total sun exposure characteristic in his place of resi­
dence, as is shown by the worldwide and intercountry variations in 
melanoma. Individual exposure habits also influence the risk, with 
SSM and NM increasing with intermittent exposures, while contin­
ued chronic exposure has a neutral or even protective effect. Inter­
mittent exposure effects appear to be stronger for SSM than for NM, 
at least in Australia, and may be site specific. SSM was increased in 
subjects with low total exposures but frequent participation in boat­
ing or fishing, and SSM of the trunk of women was positively 
associated with sunbathing at ages 15 -24, and with exposure of the 
trunk when working outdoors. Women who wore a bikini or 
bathed nude at ages 15-24, had a higher risk for trunk melanoma 
(all types) than those who wore a bathing suit that covered most of 
the trunk [18]. 
Returning to the Canadian data, we have attempted to assess this 
in a quantitative fashion, the unit of exposure being equivalent to 
1 h of exposure of the whole body to average summer daytime solar 
UV radiation at a latitude of 50° North. Exposures were calculated 
in whole-body equivalent (hereafter referred to as wbe) hours of 
exposure from data on activity, clothing, latitude, altitude, and sur­
face for occupational, recreational, and vacation activity [14]. 
The results (Fig 1) show that for both recreation and vacation 
exposures, risks increase with doses in excess of 20 wbe h, with no 
evidence of any further increase in risk at higher dosages. For occu­
pational exposure, the maximum risk is in the category of 1- 99 wbe 
hs, with a lower risk at higher exposures, beyond about 200 h. The 
analysis is limited because of the different categorizations necessary 
for the different exposures, and further work is necessary. However, 
it appears that the risk of melanoma is increased with wbe hs per 
season in excess of 20, and then falls with wbe hs of 200 or more, at 
least if this amount of exposure is achieved by a regular occupational 
type exposure. 
While there is an infinity of different personal exposures that can 
give similar totals, some typical situations can be generated. The 
dose that appears to show the lowest indication of an increased risk 
can be achieved by someone who normally has very little outdoor 
exposure, and who takes a 14-d vacation, during which 2 h per day 
for 12 of the 14 d are spent sunbathing. It could also be achieved by 
someone who has a regular boating hobby, and spends 3 h a week on 
such activities for a period of months. To put one into the very high 
exposure group, which gives a normal or even reduced risk of ma­
lignant melanoma, requires constant outdoor activity. It could be 
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Figure 1. Relative risk for cutaneous melanoma (excluding 
lentigo maligna melanoma) in relation to other exposures from 
recreation, vacation, and occupation activities. {From the West­
ern Canada Melanoma Study [14]}. 
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achieved by a beach lifeguard working 4 h a day 5 d a week for 4 
months or by an outdoor farmworker, working 7 h a day, S d a 
week f;r the full 6 months of the summer season. These two situa­
tions may have different risks, as the amount of prior exposure and 
skin acclimatization may be relevant. 
Prevention of Melanoma Although the data are complex, it may 
be reasonably inferred that a reduction in total sun or UV expos�re 
would be followed, after an unknown interval of time, by a reductIOn 
in melanoma, and that reductions in intermittent intense exposure 
may be particularly important. The data do suggest t?at, for some 
individuals, risk could also be reduced by an Increase In total expo­
sure if that involves changing from multiple irregular intense expo­
sures to a regular chronic exposure patter
.
n. Wh�le of gre�t biologic 
interest this does not seem to be useful In publIc education, as the 
amoun;s and types of exposure cannot be clear�y defined in qua�ti­
tative terms. It is reasonable to develop preventIOn programs whIch 
include the following features: 1) information that sun exposure 
and sun tanning is not a health-promoting habit; �) infor�a�ion to 
assist individual choice concerning seasonal and dlUral vanatlOns In 
UV intensity, availability and labeling of sun-blocking agents, and 
transmission of UV by clothing; 3) information on the links be­
tween sun exposure and melanoma in particular; 4) informa�lOn on 
individual features which increase risk, e.g., lIght pIgmentatIOn and 
the suggestion that exposure at ages 10-24 may be particularly 
important. 
However, the impact of most such programs has not been as­
sessed. The Queensland efforts have been cited as being success�ul 
[25], but no objective evidence for this is available. The mortalIty 
rates stabilized between 1963 - 1969 and 1977, as already noted, but 
incidence continued to increase, even the incidence of deep (Clark's 
level 3+) tumors (Table I). 
. . . Some evaluative data are available from Vlctona, AustralIa. A 
multimedia "slip slop slap" campaign from 1981-1982 was asso­
ciated with increases in the use of hats and sunscreens, and hIgh 
public awareness after the campaign was docum�nted [27]. . It is therefore important to develop such campaIgns and matenals 
carefully, with appropriate evaluation. To show the effect
.
of such 
campaigns on melanoma mortality is perhaps almost impoSSlb�e, b�t 
simpler evaluations on the effect of such. messages on p�o'
ple s atti­
tudes to sun exposure and on their behaVIor should be Imtlated. We 
do not know, for example, whether the availability of sun-blocking 
creams helps people to actually reduce their sun expo�ure, allOWing 
them to enjoy outdoor activities but reducing tanning as :veil as 
burning, or whether people use such creams mer�l� to aVOId sun­
burn, spending more time outdoors and therefore gIVing the�selves 
the same carcinogenic dosage. Messages that are too negative may 
be counterproductive. 
Early Diagnosis The aspect of melanoma control that
. 
is likely to 
have the biggest payoff in the short term IS the �eductlOn ?f case 
fatality by early diagnosis. The extremely large dIfferences In case 
fatality rates by depth of invasion at diagnosis in melanon:a are well 
recognized [6,7]. They are too great to represent a lead time effect, 
and the variation in survival in regard to the tumor bulk present at 
diagnosis is probably greater than that of most ot?er tumors. Differ­
ences in survival between AustralIa and the Umted Kingdom, and 
Table I. Incidence and Mortality Rates, Annual per 100,000 
Population, for Melanoma by Depth of Invasion, Queensland' 
Males 
Clark's Level 1963 -69 1977 
1 1.0 7.2 
2 2.0 7.2 
3-5 8.3 14.2 
Incidence, all 11.4 28.6 
Mortality 4.6 4.6 
• Derived from Refs 5 and 26. 
Ratio 1963-69 
7.2 1.4 
3.6 3.3 
1.7 9.6 
2.5 14.4 
1.0 2.6 
Females 
1977 
7.7 
9.5 
12.5 
29.8 
2.5 
Ratio 
5.5 
2.9 
1.3 
2.0 
1.0 
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the improvement in survival over 25 years in Alabama are likely to 
be largely or wholly due to earli�r dia�nosis [28,29]. . . The diagnosis of melanoma typIcally Involves: 1) recogmtlon of a 
suspicious sign or symptom, a decision by a physician to biopsy the 
lesion, and a definite diagnosis followed by therapy. The second and 
third may be combined and, if a physician is the first to notice the 
abnormality, all three may be combined. Diagnosis may therefore 
be made earlier if 1) recognition is made earlier by the lay person or 
by a professional, 2) the time interval from first si
.
g,!- to biopsy is 
shortened, and 3) no time is lost from the first phYSICIan contact to 
therapy. 
. . .  . Effects to improve the speed of dIagnOSIs WIll therefore Involve 
improving facilities for diagnosis and referral, increasing the profes­
sionals' level of expertise, and increasing the public's aware?e�s.of 
the early signs of melanoma and their importance. The pnontles 
will vary with the local circumstances. Thus, in the Umted King­
dom, results from Glasgow have shown that a combined educa­
tional approach to family doctors and the general public was fol­
lowed by an increase in the proporti?n of les.
ions < 1 .. 5 m.
m deep 
from 39% to 54% with only a small Increase In total bIOpSIes [30]. 
Discussion about applying this method in England, however, 
showed that referral facilities had to be improved first, and a number 
of pigmented lesion clinics were therefo
.
re set up in adv�n�e of a 
professional and public education campaIgn In 19�7. ThIS IS now 
being evaluated. Britain has a particular problem In that pnmary­
care physicians are not equipped to do biopsies. In Canada, mo�t 
melanomas are biopsied by the physician of first contact [21]. ThIS 
probably applies to the United States a!ld Au�tralia as.
well. Some 
findings are useful in planning e�rly dl�g.noSlS campaIgns. Ph�sl­
cians have an important role In notiCing leSIOns on routine 
checkups. In Canada, 14% of all melanomas were discovered by 
physicians, while 25% and 61 % of all cases were found by layper­
sons (such as spouses) or the patients themselves, respectively 
[21,31] (Table II). In Queensland 23% of all melanomas were dis­
covered by physicians, while 20% and �7% were found by layper­
sons or the patients themselves, respectively. The C�nadlan study 
has described in an open, unbiased manner the first sIgns of mela­
noma, as noted by the patients [21]. Sixty-five percent of all patie'!-ts 
noted, as the first suspicious sign, enlargement, color change, pain, 
or bleeding of a mole (Table II); these are the signs. Pain was not�d 
as a first symptom by 22% of all patients; but is not often recorded In 
clinical descriptions, which usually refer to the state when the pa­
tient is seen in a specialist clinic. 
In regard to improving the actions of the physician of first con­
tact, simple guidelines have been drawn by Fitzpatrick et al in the 
United States [8], and MacKie in Britain [30] among others. The 
emphasis on professional education can thus be simplified: the issue 
is not the diagnosis of a skin lesion, but the decision of whether to 
biopsy it or to refer the patient to a specialist clinic. 
Table II. First Sign or Symptom, and 
First Recognition of Melanoma' 
First Suspicion of Melanoma 
Canada 1979 -81, 651 patients 
Changes in a mole 65% 
Enlargement 
Color change 
Pain 
Bleeding 
New mole 
"Suspicious" 
8% 
24% 
Person First Noticing the Abnormality 
43 
32 
22 
16 
Canada 1979 -81 
(n = 651) 
Queensland 1979 -80 
(n = 236) 
Patient 
Other lay person 
Physician 
• From Refs 21 and 31. 
61% 
25 
14 
57% 
20 
23 
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The depth distribution of melanomas has improved rapidly in 
many parts of the world, perhaps in response to special efforts such 
as in Glasgow and in Queensland, and perhaps because of a more 
general improvement in health surveillance. Some of the trends 
may be because of changing pathologic criteria, but an international 
study involving reviews of specimens of melanomas and pigmented 
lesions, and depth measurements, from the 1950s to the late 1970s, 
has shown that such effects are minor [32]. 
Thus, the achievement of optimal early diagnosis is the top prior­
ity for melanoma control. The target may be the situation achieved 
in Australia; for example, in South Australia the five-year survival 
rate from invasive melanoma is the highest of any cancer (relative 
survival at five years 87.2%), reflecting the depth distribution with 
43% �0.75 mm and 24% 0.76- 1.5 mm [33,34]. Survival rates for 
thin melanomas are so good that perhaps they should be considered 
a preinvasive lesion analagous to in situ carcinoma of the uterine 
cervix. 
Risk Indicators-Family History and Dysplastic Nevi An 
additional method for the control of melanoma relies on the identi­
fication of subjects at substantially high risk, and the prevention of 
death from melanoma in these subjects by indentification and re­
moval of premalignant lesions, and regular surveillance so that the 
early signs of malignancy are recognized. 
The risk indicators that have received the greatest attention are 
those of a family history of melanoma and the presence of dysplastic 
nevi [35 - 38]. The main impetus for this comes from the studies by 
the National Institutes of Health (NIH) in the United States, which 
show very high risks in members of 14 specially studied families. 
Definitions of dysplastic nevi, clinical and pathologic, have been set 
out by the NIH group [35]. The NIH results have given a "lifetime" 
risk of melanoma of 100% (i.e., certainty) in subjects with both a 
family history and dysplastic nevi [37]. A NIH consensus concluded 
that proper management of subjects with dysplastic nevi "should 
significantly reduce the incidence of and the mortality from cutane­
ous malignant melanoma" [39]. A number of considerations urge 
caution in the interpretation: 
1) The data are limited. There have been 14 families studied, each 
having at least two members with melanoma, and the results relate 
to the frequency of melanoma in other family members [36] (Table 
III). The most important group is composed of family members 
who had dysplastic nevi. This group has a relative risk of 148 and a 
prospectively measured absolute risk of 7.2% over 8 years. This is 
based on 77 subjects, 398 person-years of follow-up (average 5.2 
years per subject), and four observed melanomas vs 0.027 expected. 
The eight-year cumulative risk has a large standard error: the 95% 
two-sided confidence limits are from 0.14% to 14%. 
Table III. National Cancer Institute (U.S.A.) Studies of 14 
High-Risk Melanoma Families, Each with at Least Two Affected 
Members. Risks in Family Members (Excluding Index Cases): 
Prospective Evaluation> 
Risks in Subjects Who Have 
No. of subjects 
Person-years of follow-up 
Numbers of melanomas: 
Observed 
Expected' 
Relative risk (obs./exp.) 
Rate/l00,000 p-years 
8-Year cumulative risk % 
95% Confidence limits % 
• From ref 36. 
Prior 
Melanoma & 
Dysplastic Nevi 
40 
172 
10 
0.020 
500 
5814 
33.0 
16-50 
Dysplastic 
Nevi 
77 
398 
4 
0.027 
148 
1005 
7.2 
0.14-14 
No 
Dysplastic 
Nevi 
122 
564 
o 
0.044 
o 
o 
o 
b Based on Connecticut incidence rates, averaging 8.0 per 100,000 for the whole 
group [36]. 
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2) The importance of this group, in terms of the whole problem, 
appears to be small. The central issue here is the prevalence in the 
whole population of individuals with the combination of a family 
history of two or more relatives with melanoma and the presence of 
dysplastic nevi. The NIH group estimates this as 0.014% of the 
population [37], and their data gave an incidence rate of melanoma 
of 1005/100,000 per year (approximately 1 %) in such subjects [36]. 
Consider a population of 1 million in a high-risk area, giving in 
total some 50 to 300 new cases of melanoma per year, using the 
incidence rates given at the beginning of this paper. There will be 
0.014%; that is, 140 high-risk subjects, who will have an expected 
number of 1.4 melanomas, using the NIH rate. Thus, while the 
identification and surveillance of such subjects may be important for 
research and may be useful for those subjects, it will not make a 
major impact on the whole problem of melanoma. Thus, for exam­
ple, we have not stressed it in the New Zealand melanoma control 
strategy [9]. These conclusions could, of course, change as better 
information concerning the risks, and particularly the prevalence, 
of this high-risk state becomes available. 
3) Identification and surveillance of high-risk subjects should be 
considered on an individual basis. In this regard, further results from 
the NIH studies are useful [36]. No increased risk has been seen in 
members of these families who did not themselves have dysplastic 
nevi; therefore, the risk group is composed of members of families 
with at least two persons affected with dysplastic nevi. Patients who 
have already had a melanoma are at an increased risk of subsequent 
new tumors, and, if they also have this strong family history and 
dysplastic nevi, their risk is very high: 33% at 8 years. However, 
such subjects should already be under good follow-up for their first 
melanoma. 
High-Risk Subjects: Other Risk Markers A considerable num­
ber of other risk markers for melanoma can be considered. These 
include a family history of melanoma in at least one relative, which 
gives a relative risk of 2 -5 [40], and the presence of dysplastic nevi 
without a family history of melanoma, which confers a relative risk 
of around 7 [38,40]. These, however, are lower than the risks given 
by several other simpler measures. Epidemiologic studies of mela­
noma have involved interviewing and examining patients and unaf­
fected control subjects in their own homes, using a lay or nurse 
interviewer. In these circumstances, only a very limited examina­
tion is possible, and reliable and simple methods have been devel­
oped. These can be shown to be as good at defining high-risk sub­
jects as some more-complex methods, such as those involving 
whole-body examination by dermatologists and assessments of dys­
plastic nevi. 
We have reviewed available studies in regard to their application 
to the New Zealand situation and some results are shown in Table 
IV. Thus, in two U.K. studies, the risks of melanoma in subjects 
who a) had three or more palpable nevi on the upper arm, assessed by 
a lay interviewer [41], or b) had 50 or more nevi greater than 2 mm 
in diameter on the whole body, assessed by a dermatologist [42], 
were in absolute terms very similar. In Australia, subjects who a) had 
five or more palpable nevi on the arm, assessed by a nurse inter­
viewer [16,43]' and those who b) had two or more nevi of 2 mm or 
greater diameter on the arm, assessed by a physician [44], have 
similar risks. 
This suggests that a simple method, based on a limited examina­
tion by a lay person, or even on a question and self-reporting basis, 
may be as valuable at identifying high-risk subjects as a time-con­
suming full examination by a dermatologist. However, whether 
any of these methods is a good enough risk indicator to be used on a 
large scale is unclear. Applying the Australian criteria of five or 
more raised moles isolates 7% of the population who have 28% of 
the melanomas, but a ten-year risk of only 1.8%. Thus in terms of a 
population of 1 million, identification of 70,000 subjects and sur­
veillance for ten years might lead to the early diagnosis of melanoma 
in 1,260 subjects; 68,740 would have had the surveillance unneces­
sarily. 
Whether this balance is acceptable will depend on the resources 
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Table IV. Application of Data on Risk Markers to a High-Risk Population, with an Annual Melanoma Incidence Rate of 45 per 
100,000, as Applies to Adults Aged 35-69 in New Zealand 
Incidence in 
Prevalence in 
High-Risk Subjects 
Percent of Melanomas 
Indicator Community" Relative Annual Percent, Over in High-Risk 
and Source (%) Risk' per 105, 10 YearsJ Group' 
Whole-body examinations by specialists 
1 + atypical nevi, Sydney (44) 7.1 6.6 213 2.1 34 
> 50 nevi> 2 mm, Scotland (42) 4.6 9.2 289 3.0 32 
1 + nevi with an irregular edge, Scotland (42) 1.0 37.5 1236 11.6 27 
Arm examination by general physician 
2+ nevi> 2 mm left arm, gen. physician, 25 15.8 152 1.6 84 
Queensland (54) 
Arm examination by lay examiner or nurse 
5+ palpable nevi on arms, West Australia (16, 43) 7.0 5.1 178 1.8 28 
Multiple nevi on limbs, (women only), Sydney 2.4 3.5 150 1.5 8 
(50, 55) 
3+ palpable nevi on arms, Nottingham (41) 4.8 14.4 365 3.6 41 
Subjects' response to questioning 
More than 15 moles on body, (interview), 6.0 6.7 225 2.2 30 
Nottingham (41) 
More than 100 moles on body, (questionnaire) 2.7 2.7 117 1.2 7 
New York (56) 
• Prevalence: given by frequency of marker in the unaffected, control group in the original study. 
• Relative risk: risk in those with, compared to those without, the risk marker (odds ratio). Calculated from the raw data where possible, as it is the crude ratio which is relevant. 
, Incidence: where R = relative risk. Given R = relative risk, p = prevalence of risk factor, and I = incidence in population; Ih, I,: incidence in high- and low-risk groups. 
I, = p.R.I, + (I - p)I, 
so I, = IJ(pR + I - p) and Ih = R.I,. 
• Ten-year cumulative risk = I - exp (- 1 0 . I,J. 
, Proportion of melanomas occurring in high-risk subjects 
= R.I,.p/[R.I,.p + I, (I - p)) 
= R.p/(R.p + I - pl. 
available. A useful analogy is the treatment of mild hypertension. 
The ten-year risk of a cardiovascular death in mildly hypertensive 
subjects in a large Australian trial was 2.6%, similar to the mela­
noma risks given above [45]. 
Current evidence suggests that further studies of risk indicators 
and methods of surveillance, and pilot programs capable of evalua­
tion, should be undertaken. Major continuing programs involving 
the identification and surveillance of high-risk subjects are under 
way in several U.S. centers, and their results will be valuable. How­
ever, unless such work is carried out in a defined community and the 
mortality rate for melanoma monitored, its value will be difficult to 
judge. 
MELANOMA IN JAPAN 
The epidemiology of melanoma in Japan is quite different from that 
in whites. Recorded mortality rates were about 2.2 per million 
population per year in 1980 -1984; there has been a large increase 
since 1955 -1959, where the rate was 0.5 per million per year [46]. 
The average annual percentage increase over this 25-year period 
has been 6.4%. Only a small proportion of this is due to age changes 
in the population: the age standardized rates have been increasing at 
4.7% per year. Thus, 73% of the increase in crude rates is due to 
factors other than the changing age distribution. The increases have 
been similar in both sexes: 4.8% per year for females, 4.7% for 
males. 
In Fig 2, age-standardized mortality rates for cutaneous mela­
noma in Japan from 1955-1959 to 1980-1984, given by Lee [46], 
are compared to rates standardized to the same age distribution, for 
England, Wales, the United States [47], and New Zealand. Japanese 
rates have increased more rapidly (in proportional terms) than those 
of other countries from about 1960 to 1980. The rate of increase has 
since slowed. 
Incidence rates are not available for the whole country. For the 
Fukuoka, Miyagi, Nagasaki, and Osaka registries, which contrib­
uted to Cancer Incidence in Five Continents volume four [3], the 
combined incidence rate for the period 1974-1977 was 2.6 per 
million per year, about 1.5 times the contemporary mortality rate. A 
simple extrapolation of the trend suggests the current (1988) rates 
are likely to be about 2.6 per million for mortality and 3.9 per 
million for incidence, giving about 470 new cases in the whole 
country. 
The clinical series of 842 melanomas from over 100 centers in 
Japan, described by Kukita and Ishihara in this volume, is by far the 
largest reported. Assuming these patients are representative of all 
new cases in the population, incidence rates of subtypes can be 
estimated (Table V). It is interesting to compare these to estimates 
for white populations. The estimated annual incidence of acral len­
tiginous melanoma (ALM) in Japan is 1.4 per million. In the West­
ern Canada study, which was based on a defined population [13], the 
annual incidence of all cutaneous melanoma was 79 per million, and 
13 of 665 lesions (2.0%) were ALM, giving a rate of 1.6 per million. 
Thus, the incidence of ALM appears to be similar in the Japanese 
and in this white population. 
The current incidence of ALM in Japan thus appears greater than 
the total incidence of melanoma some 20 years ago. Thus the in­
crease in incidence and mortality cannot be explained by an increase 
only in SSM and NM, the types that are largely responsible for the 
increase in melanoma in white populations. Changing sun-expo­
sure patterns, which is the main explanation suggested for the in-
Table V. Estimated Annual Incidence Rates per 
Million Population of Subtypes of Melanoma in Japan' 
Subtype 
Acral lentiginous 
Lentigo maligna 
Superficial spreading 
Nodular 
Mucosal 
Other/unknown 
Total 
Percent of 
Melanoma 
41.9 
5.3 
11.8 
28.7 
4.6 
7.6 
toO 
Incidence 
per Million 
per Year 
1.4] 
0.2 
0.4 1.5 
0.9 
0.2 
0.3 
3.3 
• Based on an estimated total incidence of 3.3 (see text), and the subtype distribution 
shown by Kukita and Ishihara (this volume). 
VOL. 92, NO.5, SUPPLEMENT, MAY 1989 
100 
50 
20 
10 
c: 
. 2 5 
's 
� 
CLI 
0-
1/1 
.s= 
-
2 0 CLI 
"0 
mole female 
0.5 0 
• HZ 
D. • US 
0 • E&W 
0 • Japan 
1950 55 60 65 70 75 80 85 
mid - year of 5 year period 
Figure 2. Trends in mortality rates from malignant melanoma of skin in 
four populations: Japan, England and Wales, United States whites, and New 
Zealand. All rates are for 5-year periods (e.g., 1951- 55, centered on 1953), 
and are standardized to the UIce "European" age distribution. 
crease in white populations, cannot therefore explain the increase in 
Japan. 
Etiology of Acral Lentiginous Melanoma The most common 
site of ALM is the sole of the foot: 68% in the recent clinical series, 
compared to 24% subungual, 6% on the palm, and 2% on other 
sites. of the 13 Canadian cases, six (46%) were on the sole. The 
etiology of acral melanoma is unknown. Trauma has been suggested 
as a cause in rural dark-skinned populations who go barefoot in 
Africa, but is argued against by the similar cases on the sole in black 
subjects in the United States, and by the current data. In an earlier 
series of subungual lesions in Japan, a concentration on the big toe 
and thumb, and on the right rather than the left, was noted [48]. 
This also suggests some influence of trauma, but these data may well 
be unrepresentative; for example, the proportion of all ALM on the 
sole was 31 % compared to 68% in the later series. Lesions on more 
important functional sites, such as the thumb, might be more often 
referred to a specialist center. 
Thus, the etiology must be considered unknown. Studies of etiol­
ogy are of particular interest because they may be relevant to other 
types of melanoma and give information about factors other than 
sun exposure. If, as suggested above, the incidence of ALM has been 
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rising in Japan, clues to etiology should exist. A case-control study 
of melanoma in Japan, perhaps linked to studies of Japanese-origin 
subjects in Hawaii and the U.S. and Canadian mainland, plus studies 
of this melanoma in other races, could be useful, primarily for de­
scriptive data. Unfortunately, trauma is particularly difficult to as­
sess retrospectively because of recall bias. 
Earlier Diagnosis in Japan Survival rates for melanoma in Japan 
are worse than those in white populations. Data presented by Sober 
in this volume give five-year survival rates for Stage I melanoma 
patients seen at Tohuka University as 65% overall, compared to 
85% in U.S. patients. Within stage I, this worse prognosis seems to 
be largely due to a less favorable depth distribution. 
An overall survival at five years of 35%, based on 41 of 81 cases 
with follow-up, was reported earlier [48], and demonstrates the 
poor stage distribution. of 616 patients with given stage in the 
recent series by Kukita and Ishihara, only 64% were stage I, com­
pared to 94% in the Western Canada series [21] . 
The conclusion suggested by these data is that there is no biologic 
reason for the poor prognosis of melanoma in Japan, but that it is a 
consequence of late diagnosis. However, as with ALM in white 
communities, the low frequency of the disease makes early diag­
nosis strategies more difficult. Simple but carefully collected data on 
the presentation and diagnosis of melanoma in Japan is needed. 
Noncutaneous Melanoma in White Populations and in 
Japan The epidemiology of ocular melanoma has been recently 
reviewed [49]. Incidence rates for all primary ocular tumors, of 
which most are melanoma in whites, range from 7 -13 per million 
in males, 4 -11 per million in females. Rates in black populations 
and in Asia are lower; Japanese registries give rates of 1-5 per 
million in males, and somewhat lower rates in females [3]. In white 
populations the epidemiology differs from that of skin melanoma. 
There has been no major secular increase, clear latitude gradient, or 
seasonal variation, although there is a positive socioeconomic gra­
dient in the United Kingdom [50]. More definite findings come 
from case-control studies, which have shown an increased risk with 
lighter iris color, and a positive association with cutaneous freckling 
[51,52]. Limited evidence suggests an association with an increased 
number of iris, but not choroidal, nevi, but no association with 
cutaneous dysplastic nevi. A positive association with sun exposure 
was found in the largest case control study, assessed through place of 
birth and outdoor activities. In the same study a strongly increased 
risk in welders was seen [51]. 
Even less is known about mucosal melanomas. In clinical series of 
whites, these usually form about 1%-2% of melanomas, but no 
unselected population-based data are available. In a review, Presant 
[53] considered some possible etiologic factors, but no conclusions 
could be reached. In the clinical series in Japan (Table V) mucosal 
melanomas comprised 4.6% of all melanoma. This suggests an inci­
dence rate of 4.6% X 3.3 = 0.15 per million in Japan. Rates in 
whites would be higher if the 1 % -2% estimate is accurate. 
Control of Melanoma in Japan It is clear that the findings 
related to cutaneous melanoma in white populations cannot be ap­
plied directly to Japan. The disease is much less common and shows 
a quite different distribution by subtype. Several research questions 
are worthy of attention. 
1) Published Japanese information consists of routine mortality 
statistics and clinical series of melanoma. A priority requirement is a 
good descriptive survey of melanoma in a defined population in 
Japan to determine the incidence and distribution by age, sex, body 
site, subtype, and depth of invasion. Such a survey would allow the 
assessment of the validity of routine mortality and incidence data, 
and the study of treatment and survival. 
2) Perhaps, originating from this survey, a case-control study of 
the etiology of melanoma could be mounted. This could be com­
bined with an assessment of presenting signs and symptoms and 
speed of diagnosis, as has been done in Canada [25]. Because this 
would require a similar number of cases but would have to be 
mounted with current identification of new patients, a major coop-
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erative effort would be needed. It would be fascinating to link this 
with a study of acral lentiginous and other unusual types of mela­
noma in the United States, which perhaps could be done via the 
SEER network, and with studies in other countries. 
3) In these studies, the questions of genetic factors and of the role 
of normal and dysplastic nevi would deserve special attention. 
4) Methods for the control of melanoma would then be based on 
the results of such studies. The data bases and cooperation generated 
would also lead to further epidemiologic laboratory and clinical 
studies. 
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